Alvotech reports financial results for first nine months of 2022 and provides business update

Reykjavik, iceland (november 15, 2022) — alvotech (nasdaq: alvo, or the “company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2022 and provided a summary of recent corporate highlights.

ALVO Ratings Summary

ALVO Quant Ranking